Study directory

Depression studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
6115studies shown
Showing 3,325-3,336 of 6,115
Drug study icon
CompletedEUCTR 2019-004018-33

Prefrontal circuits for cognitive flexibility in an extradimensional set-shifting task for humans.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about Depression.

DepressionDrugA study involving a medication or substance.
Countries
Austria
Sponsor
Department of Psychiatry and Psychotherapy, Medical University of Vienna
Condition
Depression
Drug study icon
Recruitment unclearEUCTR 2016-004422-42

A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensiv...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
France, Belgium, Bulgaria, ...
Sponsor
Janssen-Cilag International NV
Condition
Depression
Drug study icon
Recruitment unclearEUCTR 2006-005531-17

Xenon als Antidepressivum

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
Germany
Sponsor
Klinik für Anästhesiologie Universitätsklinikum Aachen
Condition
Depression
Drug study icon
Not recruitingEUCTR 2020-003720-16

A double-blind, placebo-controlled, randomized dose-ranging trial to investigate efficacy and safety of intravenous MIJ821 infusion in addition to comprehensive standard of care on the rapid reduct...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany
Why is this study shown?

This study is directly about Depression.

Depression, SuicidalityDrug
Countries
Germany, Netherlands, Poland, ...
Sponsor
Novartis Pharma AG
Condition
Depression, Suicidality
Drug study icon
Not recruitingEUCTR 2015-005081-30

Interventional, randomised, double-blind, parallel-group study of the efficacy and safety of initial administration of 17 mg vortioxetine intravenously with 10 mg/day vortioxetine orally in patient...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Estonia
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
Estonia, Finland, Lithuania, ...
Sponsor
H. Lundbeck A/S
Condition
Depression
Drug study icon
Not recruitingEUCTR 2012-001380-76

Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose long-term study to evaluate the maintenance of efficacy and safety of 1 to 3 mg/day of brexpiprazole a...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
United Kingdom, Bulgaria, Estonia, ...
Sponsor
H. Lundbeck A/S
Condition
Depression
Drug study icon
Not recruitingEUCTR 2008-005354-20

Interventional, randomised, double-blind, placebo-controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 12 to 17 years, with Major depressive disor...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium
Why is this study shown?

This study is directly about Depression.

DepressionDrug
Countries
France, United Kingdom, Belgium, ...
Sponsor
H. Lundbeck A/S
Condition
Depression
Other study type icon
Not recruitingISRCTN60175188

The cognition game study

This study is looking at whether a digital support tool can help people with Cognitive impairment in psychiatric (we included subjects with schizophrenia/schizo-affective disorder, depression and OCD or Mental and Behavioural Disorders. Participants receive a study treatment and complete follow-up visits and assessments.

In Netherlands
Why is this study shown?

This study is directly about Depression.

Depression, OCD, ...Other
Countries
Netherlands
Sponsor
MyCognition
Condition
Depression, OCD, ...
Drug study icon
CompletedNCT05059600

Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting

This study is completed in the United States. It is testing Safe-Use Conditions for Depression.

Multiple locations, including Culver City
Why is this study shown?

This study is directly about Depression.

DepressionDrugOver 18 Years
Countries
United States
Sponsor
Supernus Pharmaceuticals, Inc.
Condition
Depression
Behavioral study icon
WithdrawnNCT03804619

Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder

This summary needs review. Please check the official study record and contact the research team for details.

In Palo Alto
Why is this study shown?

This study is directly about Depression.

Depression, SuicidalityBehavioralOver 18 Years
Countries
United States
Sponsor
Stanford University
Condition
Depression, Suicidality
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.